financetom
Business
financetom
/
Business
/
Adobe to offer free app to help with labeling AI-generated content
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Adobe to offer free app to help with labeling AI-generated content
Oct 10, 2024 11:41 PM

(Reuters) - Adobe said on Tuesday it will offer a free web-based app starting next year, aimed at helping the creators of images and videos to get credit for their work used in AI systems.

    Since 2019, Adobe and other technology companies have been working on what the firms call "Content Credentials," a sort of digital stamp for photos and videos around the web to denote how they were created.

TikTok, which is owned by China's ByteDance, has already said it will use Content Credentials to help label AI-generated content.

    San Jose, California-based Adobe said it will offer a free service to allow the creators of photos and videos to affix Content Credentials to their work.

In addition to indicating that they authored the content, the creators can also use the free app to signal if they do not want their work to be used by AI training systems that ingest huge amounts of data, the company said.

    The use of data in AI training systems has sparked legal responses in multiple industries, with publishers such as the New York Times suing OpenAI, while some other firms have opted to work out licensing deals.

    As yet, no large AI company has agreed to abide by Adobe's system for transparency. In a release, Adobe said it was "actively working to drive industry-wide adoption" of its standards.

    "By offering creators a simple, free and easy way to attach Content Credentials to what they create, we are helping them preserve the integrity of their work, while enabling a new era of transparency and trust online," Scott Belsky, chief strategy officer and executive vice president for design and emerging products at Adobe, said in a statement.

(Reporting by Stephen Nellis in San Francisco; Editing by Shinjini Ganguli)

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Immunovant's muscle disorder treatment meets main goal in late-stage trial
Immunovant's muscle disorder treatment meets main goal in late-stage trial
Mar 19, 2025
March 19 (Reuters) - Immunovant ( IMVT ) said on Wednesday its drug for a type of a chronic autoimmune disease that causes muscle weakness met the main goal in a late-stage trial. ...
Top Premarket Decliners
Top Premarket Decliners
Mar 19, 2025
07:54 AM EDT, 03/19/2025 (MT Newswires) -- 5E Advanced Materials ( FEAM ) shares were down 19% pre-bell Wednesday, reversing Tuesday's gains. HealthEquity ( HQY ) stock was 17% lower after the company reported late Tuesday fiscal Q4 non-GAAP earnings that trailed analysts' estimates. Turkcell Iletisim Hizmetleri (TKC) shares were down 13% following a muted session. ...
Boyd Group Q4 Profit Plunges Despite Higher Sales
Boyd Group Q4 Profit Plunges Despite Higher Sales
Mar 19, 2025
07:53 AM EDT, 03/19/2025 (MT Newswires) -- Boyd Group Services ( BYDGF ) , one of the largest operators of non-franchised collision repair centers in North America, on Wednesday said fourth-quarter profit plunged as acquisition and transformational cost initiatives impacted results. Net earnings for the three months ended Dec. 31 fell to US$2.4 million or US$0.11 per basic and diluted...
XORTX Therapeutics Announces Type B Meeting With FDA
XORTX Therapeutics Announces Type B Meeting With FDA
Mar 19, 2025
07:55 AM EDT, 03/19/2025 (MT Newswires) -- XORTX Therapeutics ( XRTX ) , which is developing therapies to treat progressive kidney disease and gout, on Wednesday said it has prepared a broad Type B meeting package at the request of the Food and Drug Administration. The package to be submitted includes a review of chemistry, manufacturing, pharmacology, toxicology and clinical...
Copyright 2023-2026 - www.financetom.com All Rights Reserved